These results indicate that immunogenic rejection of tumors is Batf3 dependent but not limited to DC ability to cross-present tumor antigens, and there might be other mechanisms involved, such as the ability of cDC1s to communicate with other immune cells through the secretion of CXC-chemokine ligand 9 (CXCL9) and CXCL10, which induce recruitment and infiltration of T cells at the tumor site (Perez and De Palma, 2019). The gene discussed is CXCL9; the disease is neoplasm.